Products in Development


Oncology Preferences And Risk of Toxicity

Designed to predict risks for 6 clinically significant & costly side effects due to chemotherapy regimens while also including a tool for quantifying patient’s willingness to tolerate them

In the first phase of OnPART™ development, interactive SNP networks demonstrated >90% accuracy with biologic validity for 12 of 12 networks predictive of significant chemotherapy side effects.

— see poster —

  1. Nausea & vomiting
  2. Diarrhea
  3. Peripheral neuropathy
  4. Oral mucositis
  5. Cognitive dysfunction
  6. Fatigue

The Problem

Chemotherapy-induced Side Effects
  • Patients receiving chemotherapy averaged $111,000/year in total medical & pharmacy costs
  • ~40% identified as chemotherapy-related
  • Mortality rate associated with hospitalization for chemotherapy-related side effects has been reported as high as 6%
  • On an individual basis, the costs of chemotherapy-related side effects are striking:
  • Incremental expenditures for hospitalizations = $12,907/person/year
  • Prescriptions = $1,908/person/year & prescription copayments ($120/person/year) compared with those who did not have chemotherapy-related adverse effects.

How We Help

OnPART™ adds value & benefit
  • Patients
    by reducing the burden of debilitating side effects & successfully finishing their treatment plan
  • Providers
    by providing actionable information to tailor a patient’s chemotherapy regimen and to plan supportive care strategies
  • Payers
    by reducing the high cost of managing side effects

Hypothetical Case Study

Mrs. Smith is a 75-year-old piano teacher, diagnosed with metastatic colon cancer
  • There are a number of chemotherapy regimens that could be used to treat her—all have comparable therapeutic efficacy, but differ in side-effect profiles
  • Appropriate choices of chemotherapy regimens include*:

–FOLFOX +/- bevacizumab

–FOLFIRI +/- bevacizumab

–CAPEOX +/- bevacizumab

–FOLFOXIRI +/- bevacizumab

Mrs. Smith’s doctor:

  1. Sends a saliva sample to Inform Genomics CLIA lab for a genomic risk assessment
  2. Asks Mrs. Smith to complete a Preference Assessment Inventory©

Actionable Outcome

  • Mrs. Smith is least willing to tolerate diarrhea & Peripheral Neuropathy;
    yet she is at high risk for diarrhea PN from several regimens.
  • Mrs. Smith and her doctor agree on a cancer care
    plan based on her genomic risk and preferences including prevention of diarrhea with loperamide & octreotide.


OnPART™ Summary of Benefits

For Patients:

Provides an opportunity to reduce the burden of debilitating side effects, gives them best chance to maintain planned chemotherapy with intended benefit (response, survival)

Offers them a voice in their own care

For Providers:

A new tool to identify patients at risk for common side effects of chemotherapy before starting chemotherapy

Information they can act on—to pre-plan supportive care strategies, consider therapeutically equivalent chemo regimens & avoid known
side-effect risks, council patients & individualize informed consent

Individualize a patient’s cancer care plan

For Payers:

Affords payers a new way to manage the high, downstream costs associated with chemotherapy-related side effects


Hematopoietic Stem Cell Transplant / Oral Mucositis

Predict patient risk for developing highly debilitating Oral Mucositis due to high-dose chemotherapy regimens prior to Hematopoietic Stem Cell Transplant (HSCT)

The Problem

Among HSCT patients, ulceration is associated with additional
  • 2.0 days of fever
  • 3.4 days of hospitalization
  • 5.8 days of intravenous opioid analgesics
  • 1.9 days of total parenteral nutrition

The Costs

The additional resources translate into increased hospital costs of >$42,000 per patient.


Proof of concept for HSCT/Mucositis™ 

  • In the first phase of development, the HSCT/Mucositis™ product demonstrated that it could predict, with a high degree of accuracy, a patient’s OM risk
  • Cofounder Dr Steve Sonis’s first paper won award for best original research in Oral Diseases

HSCT/Mucositis™ positioned to improve lives & reduce total cost

  • The HSCT/Mucositis™ product has been designed to identify which patients in the transplant setting are most at risk for OM so that primary prevention can be a part of the supportive care plan, eg:
  • Palifermin
  • Dose modification
  • This genomic-based, risk information can help minimize the clinical and economic impact of this serious side effect